|
Business Support:
Aneta Zych
☎ +48 (0) 22 334 9810
+48 (0) 22 334 9875
aneta.zych@paiz.gov.pl
Ewa Kowalczyk
☎ +48 (0) 22 334 9874
ewa.kowalczyk@paiz.gov.pl
Poland - emerging biotechnology market
There is significant potential in research in the Polish biotechnology sector and though the country’s industry is concerned mainly with the presentation and distribution of imported finished goods, many indicators show that transformation towards highly advanced biotech sector is already on the way.
The development of bio-substances and bio-fuels, that are meant to replace coal and particularly crude oil, is a traditional Polish specialty. Among particularly valuable substances produced in Poland there are: hormones, cloned antibodies and diagnostic tests, all generated with the use of modern genetic engineering techniques.
The fastest development in Polish biotech is to be observed in the field of biopharmacology with the improvement of the manufacturing processes of human proteins and peptides based on E.coli and cell cultures. Undoubtedly there still is a considerable scope for exploitation of the untapped potential in the section of vaccines, protein drugs, diagnostic tests and reagents. Among other potential sector driving forces are: insulin, erythropoietin, interferons, monoclonal antibodies.
Biotechnology split presents as follows:
Red - 50%
Green - 15%
White - 30%
Poland is well prepared for development in each of the above biotechnology sectors.
The most significant factor, why Poland is one of the world’s most attractive locations for international biotechnology operations, are highly educated young scientists graduating from Polish universities. Poland’s biotechnology sector is represented by numerous companies, 8 000 biotech students and 1 300 graduates a year, 36 universities lecturing biotechnology (30 of which offering Ph.D studies).
As biotechnology is a priority sector for the Polish economy, the government supports new investments in the sector. Investment incentives, including government grants and EU funds, are available. Only within the EU Innovative Economy Operational Programme there is almost EUR 10 Bn to apply for between 2007-2013.
Among all biotech companies in Poland over 30 are diagnostic enterprises responsible for R&D, implementation of services in pharmaceutical products, food & cosmetics control.
Benefits to be gained from biotechnology investments in Poland:
high research potential (diversified research areas covered by specialized institutions)
very well trained personnel
favorable government policy supporting investments in new technologies
developed raw materials base
development of biotechnology-related sectors
competitive labour costs
investment incentives for biotech project
Map of biotech sector in Poland
Useful links:
Biotech associations in Poland
www.pfb.p.lodz.pl - Polish Federation of Biotechnology
www.ekoland.org.pl - Organic Food Producers Association
www.dziedzictwonatury.pl - Association for balanced sustainable development of life on Earth
em-world.nazwa.pl - Association for the care of the natural ecosystems
www.efb-central.org - European Federation of Biotechnology
www.europabio.org - European Association of Bioindustries
www.assb.pl - Academic Student Association of Biotechnology
Biotech news
www.biotechnolog.pl
www.biotechnologia.pl
www.CEbiotech.com
www.eufic.org
www.cabi.org/agbiotechnet
www.biosecuritycodes.org
www.lifesciencesworld.com
www.gmo-compass.org
www.icgeb.org/~bsafesrv |
